Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01109095 · ClinicalTrials.gov registry record · Phase 1
CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
A Phase 1 study of Glioblastoma Multiforme (GBM), sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT01109095 is a Phase 1 study of Glioblastoma Multiforme (GBM) that has completed, run by Baylor College of Medicine. The registered enrollment target is 16 participants, below the 69-participant average among 5 other Glioblastoma Multiforme (GBM) trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01109095, a Phase 1 study of Glioblastoma Multiforme (GBM), has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is for patients that have a type of brain cancer called glioblastoma multiforme (GBM). The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat patients with cancers. They have shown promise, but have not been strong enough to cure most patients. The antibody used in this study is called anti-HER2 (Human Epidermal Growth Factor Receptor 2). This antibody sticks to GBM cells because of a substance on the outside of these cells called HER2. Up to 80% of GBMs are positive for HER2. HER2 antibodies have been used to treat people with HER2-positive cancers. For this study, the HER2 antibody has been changed so that instead of floating free in the blood it is now attached to T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These chimeric receptor-T cells seem to be able to kill tumors like GBM, but they don't last very long and so their chances of fighting the cancer are limited. Therefore, developing ways to prolong the life of these T cells should help them fight cancer. We found that T cells work better if we also attach a protein called CD28 to the HER2 chimeric receptor (HER2-CAR). In this study we placed this HER2-CAR into T cells that were pre-selected for their ability to recognize Cytomegalovirus (CMV). This virus exists in most people. These CMV-specific cytotoxic T cells (CMV-T cells) will be more active since they will react to the virus as well as to tumor cells. These HER2-CD28 CMV-T cells are an investigational product not approved by the Food an
Conditions Studied
Interventions
- BIOLOGICAL HER.CAR CMV-specific CTLs
Study Locations (2)
Texas
- Houston Methodist Hospital - Houston
- Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-10 |
| Est. Completion | 2018-03-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01109095
The ClinicalTrials.gov registry entry for NCT01109095 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 69-participant average among 5 other Glioblastoma Multiforme (GBM) trials with a reported enrollment target (77% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma Multiforme (GBM) appearing as the primary indexed condition, and to 1 intervention - of which HER.CAR CMV-specific CTLs is the first listed.
NCT01109095 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01109095 about?
NCT01109095 is a clinical study titled "CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM". This study is for patients that have a type of brain cancer called glioblastoma multiforme (GBM). The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cel...
What is the current status of trial NCT01109095?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2010-10. Estimated completion is 2018-03-07.
What conditions does trial NCT01109095 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme (GBM).
What interventions are being tested in trial NCT01109095?
The interventions under investigation include: HER.CAR CMV-specific CTLs (BIOLOGICAL).
Who is sponsoring clinical trial NCT01109095?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01109095 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme (GBM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
-
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA
COMPLETED · Phase 1
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.